1. Home
  2. PCRX vs DRUG Comparison

PCRX vs DRUG Comparison

Compare PCRX & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$23.05

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$80.67

Market Cap

856.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
DRUG
Founded
2006
2019
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
856.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PCRX
DRUG
Price
$23.05
$80.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
6
Target Price
$35.33
$106.75
AVG Volume (30 Days)
775.3K
120.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.21
N/A
Revenue Next Year
$8.26
N/A
P/E Ratio
$48.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.80
$23.18
52 Week High
$27.64
$123.75

Technical Indicators

Market Signals
Indicator
PCRX
DRUG
Relative Strength Index (RSI) 58.70 49.93
Support Level $20.88 $74.21
Resistance Level $21.60 $84.66
Average True Range (ATR) 0.80 5.51
MACD 0.39 0.31
Stochastic Oscillator 93.52 65.47

Price Performance

Historical Comparison
PCRX
DRUG

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: